Q-omics provides the consensus-scored ODAM profile across patient tissues and cancer cell-line models. ODAM expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ODAM is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ODAM RNA expression shows 11,772 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where ODAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ODAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ODAM survival associations across molecular data types. ODAM RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ODAM RNA expression–survival associations across cancer types. High ODAM expression shows unfavorable associations in KIRP and TGCT, but favorable associations in LUAD, STAD, BLCA and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ODAM RNA expression.
This table summarizes ODAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ODAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ODAM shows lower tumor expression in KIRC, THCA, LUAD, KIRP and LUSC and higher tumor expression in COAD. The KIRC box plot shows higher ODAM RNA expression in normal versus tumor tissue (log2 FC = −1.713, t-test p < 0.001).
This table shows molecular features associated with ODAM in patient tissues and cancer cell lines. In patient samples, ODAM shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ODAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
